Agenda
-
Coffee and registration
-
Chair:
- Session 1: Updates from the authorities
-
Update from the commission: Latest developments in the biocides field
- Active substances
- Product authorisation
- Endocrine disruptors
- Treated articles
- Implementation & enforcement
-
ECHA’s latest updates
- Review programme progress
- Union authorisations
- Regulatory IT developments
- Dissemination
- Support to industry
-
Q&A
-
Refreshments
- Session 2: Risk Assessment
-
Environmental Risk Assessment of disinfectants – new aspects and developments
- Environmental risk assessment of disinfectant products
- Emission Scenarios for disinfectants
- Challenges and ways forward
-
The new ECHA guidance for disinfection by-products
- Background on the disinfection by-products formation
- Product types relevant for the risk assessment
- Approach to the Human Health Risk Assessment
- Approach to the Environmental Risk Assessment
-
Estimating consumer exposure via biocide residues in food
- Domestic use of disinfectants and insecticides
- ECHA Guidance on non-professional uses
- Models for estimating consumer exposure
-
Q&A session
-
Human Health Risk Assessment; an overview of exposure modelling
- What is exposure modelling
- Why is it needed
- Summary of available guidance
- Overview of available models and their usefulness
- What to do if there is no model
-
Human Health Risk Assessment for in-situ products
- Basics of in-situ products and assessments
- Data requirements for human health
- Models and tools for estimating human exposure
- Tips, tricks and pitfalls
-
Q&A
-
Lunch
- Session 3: Efficacy
-
Update on the ECHA Efficacy Working Group
- Guidance
- Active substance
- Union authorisation
- MR referrals
-
Repellents' and attractants' efficacy – Lessons learned and new challenges
- Link between efficacy and mode of action of active substances
- PT 19 in new efficacy guidance
- Common problems in testing design
- Market needs and efficacy challenges
Karolina Pastuszko
Chief Specialist, The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products - Session 4: Brexit and the BPR
-
Brexit and Biocidal: In search of enhanced predictability
- Timing and state of play
- Active substance dossiers under review by HSE
- Product authorisation issues
- Article 95 BPR: status of UK-based companies
- Contractual issues
- UK participation in international fora
-
Q&A
-
Refreshments
- Session 5: Borderline issues
-
Case studies of chemicals regulated under the BPR, PPPR and REACH: what can we learn?
- Overview of regulatory procedures and regulatory bodies involved
- Case studies of substances regulated under different legislations
- Borderline case BPR/PPPR
- Session 6 - Experiences with Active Substance Approval/Renewal, part I
-
AS and product renewals – an industry perspective
- The process
- Timelines
- Learning from our experience
- How to improve the process
-
Q&A
- Session 7 - 20th Anniversary of the Vienna Biocides Conference
-
Panel Discussion - looking back over the past 20 years of Biocides Regulation and looking forward
Edmund Plattner
Consultant, former Head of Biocides Division, Ministry of Agriculture, Forestry, Environment and Water Management
Roland Solecki
Director, Head of Department Pesticide Safety, Federal Institute for Risk Assessment (BfR) -
Close of day one
